File downloaded on 2026-10-29
Source URL: https://medicines.health.europa.eu/veterinary/en/600000984519

Bovilis Nasalgen-C (--) - Nasal spray, lyophilisate and solvent for suspension

Authorised

- Bovine coronavirus, strain CA25, Live

Product identification

Medicine name:
Bovilis Nasalgen-C (--) - Nasal spray, lyophilisate and solvent for suspension

Active substance:
Bovine coronavirus, strain CA25, Live

Target species:
Cattle

Route of administration:
Nasal use

Product details

Active substance and strength:
Bovine coronavirus, strain CA25, Live

Presentation_strength:≥ 5.4 log_{10} $TCID_{50}$ ≤ 7.8 log_{10} $TCID_{50}$ Reference:Hse Index:0

Pharmaceutical form:

Nasal spray, lyophilisate and solvent for suspension

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AD10

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Czechia , Denmark , Finland , France , Germany , Hungary , Ireland , Italy , Luxembourg , Netherlands , Poland , Portugal , Romania , Slovakia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophlisate: 1 dose; solvent: 2 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vials + solvent: 1 vial, Content:Lyophilisate: 5 doses + solvent: 10 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophlilsate: 10 doses + solvent: 20 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 doses; solvent: 10 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 x 5 doses + solvent: 5 x 10 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 x 10 doses + solvent: 5 x 20 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial+ solvent: 1 vial, Content:Lyophilisate: 20 doses + solvent: 40 ml
Packaging:Lyophlisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophilisate: 50 doses + solvent: 100 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
31/03/2023

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
31/03/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 14/03/2026

Download

ema-puar-v5906-bovilis-nasalgen-c-en.pdf